Insulin secretion is thought principally to be regulated by blood glucose concentration. Three recent studies emphasise the additional importance of fatty acids as regulators of insulin secretion, and demonstrate the involvement of a novel G proteincoupled receptor.
gave similar results, though they were also able to demonstrate small differences in the relative potencies of different fatty acids, with linoleic acid (C18:2) having half-maximal effects at the lowest concentration (1.8 µM). This group also showed that the effective fatty acids had no effect on intracellular levels of cyclic (c)AMP. Kotarsky et al. A remarkable aspect of the new results is that the expression of GPR40 mRNA in rats was almost exclusively confined to the pancreas, with very minor expression in the upper intestine [12] . The latter finding is also of interest as it may be linked to the ability of free fatty acids to stimulate the release from the gut of cholecystokinin, a potential satiety factor [17] . In humans, GRP40 mRNA was strongly expressed in both pancreas and brain [11, 13] . Two observations suggest that GPR40 expression is largely confined to islet β β-cells: first, GPR40 expression was increased in the islets of genetically obese (ob/ob) compared to lean (wild type) mice, in parallel with an increase in β β-cell number; and second, GPR40 mRNA was found to be highly abundant in clonal β β-cells [11-13], but absent from pancreatic α α-cells and exocrine pancreas-derived cell lines.
Consistent with these findings, oleic (C18:1) and linoleic (C18:2) acid markedly potentiated insulin release from MIN6 β β-cells at permissive glucose concentrations (> > 5.5 mM), but had no effect in the complete absence of glucose [12] . Crucially, small interfering (si)RNAs [18] expected selectively to silence GPR40 expression strongly inhibited the ability of fatty acids to stimulate insulin release.
The new studies, though undoubtedly important, do leave some unanswered questions. It is not yet clear, for example, whether the small differences in the apparent efficacy of saturated versus unsaturated fatty acids to activate GPR40 will be reflected in vivo, and whether they are related to the well-known health benefits of a diet richer in the latter. Secondly, we do not yet know whether GPR40 also plays a role in the triggering of secretion by glucose. Such a prospect is tantalizing as glucose-induced accumulation of malonyl-CoA, which inhibits fatty acid oxidation [19] , and the generation of fatty acids such as arachidonate [10] , have both been described in β β-cells and could conceivably act, at least in part, by stimulating GPR40 (Figure 1) . But it seems unlikely that the release of fatty acids contributes to the K ATP -independent pathway of glucose-stimulated insulin secretion [3] , as this is observed even when intracellular [Ca 2+ ] is clamped [3] . Finally, whilst the studies with siRNA on isolated clonal cells are informative [12] , complete understanding of the role of these receptors will require their inactivation both in intact isolated islets and in the β β-cells of live mice.
The new studies provide important insights into a number of previously puzzling aspects of nutrientsecretion coupling in islets. In particular, they may explain why fatty acids, like other important G proteincoupled agonists such as glucagon-like peptide-1 [20] , act as 'potentiators' rather than 'initiators' of insulin secretion. Both agonists thus act only in the presence of elevated glucose concentrations -clearly an important safeguard during starvation where free fatty acid levels can be elevated but insulin release is undesirable. Agonists of GRP40, and possibly other, as-yet unidentified G protein-coupled receptors, may thus provide important new drug targets for the treatment of type 2 diabetes which avoid the risk of hypoglycaemia. 
